Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Yakult Of Japan To Introduce Liver Cancer Drug From U.S. Firm Celsion

This article was originally published in PharmAsia News

Executive Summary

Yakult announced Aug. 19 that the company and U.S. bioventure company Celsion executed a letter of intent relating to the commercialization of liver cancer drug ThermoDox for the Japanese markets. Yakult will start preclinical and clinical studies required for approval in Japan. The amount of payment and market rights are subject to a definitive agreement. Currently in final development in the U.S, Canada and Italy, the drug is estimated to be approved overseas as early as 2010. Yakult has focused on increasing its healthcare division to 10 percent of the company's business in 2008. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts